No Data
Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.
As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.
TIGERMED (300347.SZ): The current tariff policy in the USA mainly imposes additional duties on products, but it has no significant impact on the company at this time.
On April 15, Gelonghui reported that TIGERMED (300347.SZ) stated on the interactive platform that the company is a contract research organization (CRO) focused on providing comprehensive Professional Services for the entire process of clinical trials for new drug development. It offers comprehensive and integrated clinical research solutions for Global pharmaceutical and medical instruments innovation companies. The services primarily include clinical trial technical services and related laboratory services. Currently, the USA's tariff policy primarily imposes additional tariffs on products, which has no significant impact on the company. The company will continue to monitor the developments in USA's tariff policy.
Hong Kong stocks close | Under the shadow of tariffs, major indices performed unevenly. ZHOU HEI YA surged nearly 8%, leading the Consumer stocks to break through.
① How did Trump's tariff policy lead to a divergence in the Hong Kong stock market? ② Why does HTSC still recommend allocating to Hong Kong stock dividend direction despite tariff disruptions?
Research Reports Gold Mining | Zheshang: Maintaining a "Buy" rating for TIGERMED, with internationalization expected to enter an accelerated phase.
Zheshang's Research Reports indicate that TIGERMED (300347.SZ) will achieve a revenue of 1.536 billion yuan in Q4 2024 (YOY -11.42%), with a net income of -0.037 billion yuan after exclusion. The net cash flow generated from operating activities for 2024 is 1.097 billion yuan (a year-on-year decline of 4.64%), which has shown significant improvement compared to H1 2024 and is believed to be related to the company's enhanced payment management in the second half of the year. Looking forward to 2025, it is believed that the impact from the large clinical business base and reduction will be one-time effects. With the execution of orders and stabilization of order prices, the gross margin for the large clinical business is expected to return to a relatively high level.
Caitong: Innovative Drugs and Medical Devices remain an important main line in this round of the bull market in the Medical industry.
The country is likely to accelerate the introduction of policies to encourage expanded domestic demand, which is Bullish for the sectors focused on domestic consumption, including Traditional Chinese Medicine, Medical Services, Internet medicine and pharmacies, medical aesthetics, etc., as an extension of the Health China logic.
Tariffs Loom as US Investigates Drug and Chip Imports
